Table 1. Characteristics and outcomes of patients with myocarditis related to mpox and summary of pooled data from included published research papers have been reported in the literature (n=12).

Author/Year of publication	Shaik et al. (2022) [56]	Rodriguez- Nava et al. (2022) [4]	Brouillard et al. (2022) [49]	Tan et al. (2022) [57]	Pinho et al. (2022) [44]	Guerrero et al. (2023) [58]	Dumont et al. (2022) [50]	Luis et al. (2023) [59]	Krainin et al. (20223) [60]	Total
Country	USA	USA	Canada	Canada	Portugal	Spain	France	Puerto Rico	USA
Study design	Case report	Case series	Case report	Case report	Case report	Case report	Case series	Case report	Case report
Sample size	1	2	1	1	1	1	3	1	1
Age (year)	51	32 and 37	34	40	31	40	21, 25 and 32	21	31	32.9 years
Gender	Male	Male	Male	Male	Male	Male	Male	Male		100% male
Days to symptom	7	15 and 13	3	12	8	14	6, 5 and 10	9	NR	8.4 days
onset
Presenting	Chest pain	Chest pain	Chest pain,	Chest pain	Chest pain	Chest pain	Chest pain	Chest pain,	Chest pain,	Chest pain,
symptom			dyspnea					dyspnea	dyspnea	dyspnea
Treatment	NSAIDs,	Tecovirimat,	Tecovirimat,	NR	NSAIDs	Tecovirimat,	Tecovirimat,	Aspirin	Tecovirimat,
	colchicine,	supportive	ACE inhibitor,			NSAIDs,	bisoprolol,		supportive
	aspirin,	care	NSAIDs			colchicine	ramipril		care
	nitroglycerin
Follow-up (day)	7	10 and 4	10	25	7	6	30, 4 and 30	5	NR	12.5 days
Outcome	Recovered	Recovered	Recovered	Recovered	Recovered	Recovered	Recovered	Recovered	Recovered	100% recovered

NSAID: non-steroidal anti-inflammatory drug, NR: non reported